A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis | MicrobiomeTrials
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2024-06-25Est. Completion: 2028-08-21
Enrollment target: 168 participants
Locations
Ps0021 50162, Fountain Valley, California, United States
Ps0021 50161, Los Angeles, California, United States
Ps0021 50196, Northridge, California, United States
Ps0021 50581, Miami, Florida, United States
Ps0021 50344, Indianapolis, Indiana, United States
Ps0021 50599, Kew Gardens, New York, United States
Ps0021 50084, Charleston, South Carolina, United States
Ps0021 50201, Arlington, Texas, United States
Ps0021 50355, Dallas, Texas, United States
Ps0021 40121, Brussels, Belgium
Ps0021 40420, Liège, Belgium
Ps0021 50618, Mississauga, Canada
Ps0021 50357, St. John's, Canada
Ps0021 50617, St. John's, Canada
Ps0021 40748, Plzen-bory, Czechia
Ps0021 40742, Argenteuil, France
Ps0021 40754, Nantes, France
Ps0021 40740, Bad Bentheim, Germany
Ps0021 40515, Berlin, Germany
Ps0021 40138, Bonn, Germany
Other microbiome trials you might be interested in